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The importance of CD4 T cells in orchestrating the immune system and their role in induc-
ing effectiveT cell-mediated therapies for the treatment of patients with select established
malignancies are undisputable. Through a complex and balanced array of direct and indi-
rect mechanisms of cellular activation and regulation, this functionally diverse family of
lymphocytes can potentially promote tumor eradication, long-term tumor immunity, and
aid in establishing and/or rebalancing immune cell homeostasis through interaction with
other immune cell populations within the highly dynamic tumor environment. However,
recent studies have uncovered additional functions and roles for CD4 T cells, some of
which are independent of other lymphocytes, that can not only influence and contribute
to tumor immunity but paradoxically promote tumor growth and progression. Here, we
review the recent advances in our understanding of the various CD4 T cell lineages and
their signature cytokines in disease progression and/or regression. We discuss their direct
and indirect mechanistic interplay among themselves and with other responding cells of
the antitumor response, their potential roles and abilities for “plasticity” and memory cell
generation within the hostile tumor environment, and their potentials in cancer treatment
and immunotherapy.
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INTRODUCTION
Cancer cells express antigens that differentiate them from their
non-transformed counterparts (Van Der Bruggen et al., 2002).
These antigens are often products of mutated cellular genes, aber-
rantly expressed normal genes, or genes encoding viral proteins.
Categories and examples of human tumor antigens thus far iden-
tified include (a) the differentiation antigens encoded by genes
that are only expressed in particular types of tissue such as those
antigens expressed in melanocytes and melanoma and involved in
melanin production, (b) mutational antigens that arise as a con-
sequence of gene rearrangement and point mutations (i.e., p53),
(c) cellular antigens that are over expressed in transformed cells
when compared with their normal counterparts (i.e., HER-2), (d)
molecules that display abnormal post-translational modifications
(i.e., MUC1), (e) viral antigens derived from viral oncogenes (i.e.,
human papillomavirus proteins), and (f) cancer/testis (CT) anti-
gens that are expressed in germ cells of testis and ovary but silent
in normal somatic cells (i.e., MAGE and NY-ESO-1) (Cheever
et al., 2009). It has been shown that tumors co-expressing such
antigens can be recognized by effector T cells of the adaptive
immune system and induce antitumor immune responses in both
experimental animal and human systems (Dougan and Dranoff,
2009).
One of the earliest processes involved in the development of the
adaptive immune response and tumor immunity is inflammation
which functions to localize and eradicate tissue stressors induced
by tumor growth and re-establish normal tissue homeostasis
(Medzhitov, 2008). However, evidence obtained from various
murine tumor models and clinical studies in cancer patients, have
shown that chronic inflammation, mediated by ensuing adaptive
immune responses, can contribute to tumorigenesis at all stages.
For example, such responses may contribute to cancer initiation
by generating genotoxic stress, to cancer promotion by induc-
ing cellular proliferation, and to cancer progression by enhancing
angiogenesis and tissue invasion (Grivennikov et al., 2010). In
either instance, this forms the conceptual framework of the cancer
immunoediting hypothesis,which stresses the dual host-protective
and tumor-promoting actions of immunity on developing tumors
(Schreiber et al., 2011; Vesely et al., 2011). In its most simplistic
form, this model proposes that tumors develop through three suc-
cessive and distinct phases termed “elimination,” “equilibration,”
and “escape.” The elimination phase entails the process where the
innate and adoptive immune systems collaboratively detect the
presence of a developing tumor and destroy it before it becomes
clinically apparent. The next phase of equilibration entails the
process where rare tumor cell variants survive immune-mediated
elimination and enter a state of equilibrium with the adaptive
immune response. In this state, the immune system maintains
residual tumor cells in a functional state of dormancy, a term used
to describe latent tumor cells that may reside in patients for decades
before eventually resuming growth as either recurrent primary
tumors or distant metastases (Aguirre-Ghiso, 2007). Aside from
preventing tumor outgrowth, it is also believed that the immune
response in this phase “fashion” the immunogenicity of the occult
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tumors. Lastly, in the escape phase, tumor cells that have acquired
the ability to circumvent immune recognition and/or destruc-
tion emerge as progressively growing and detectable tumors. It
is further postulated that the course and progression through such
phases are influenced and determined, in part, by tumor cell pop-
ulation changes in response to the immune system, host immune
system changes in response to mechanisms re-establishing cellular
homeostasis, or increased cancer-mediated immunosuppression
and/or immune system decline. Such local and systemic envi-
ronmental stressors are thought to be the major contributors
to affect not only tumor outgrowth but also immunotherapeu-
tic interventions and their efficacy in cancer patients. Thus, the
tumor-promoting inflammation and protective tumor immunity
processes appear dynamically interconnected where an imbal-
ance can further result in the shaping of tumor immunogenicity
which may either initiate and/or facilitate disease progression or
regression.
At the earliest stages of the antitumor immune response, profes-
sional antigen presenting cells (APCs), most notably dendritic cells
(DCs), encounter and capture tumor antigens that are released
from either viable or dying tumor cells. This results in the activa-
tion and up-regulation of co-stimulatory molecules that facilitate
and/or promote the migration of these cells to secondary lym-
phoid organs such as regional draining lymph nodes (Steinman
and Mellman, 2004; Steinman and Banchereau, 2007). To develop
into potent CD4 effector T cells that contribute to the antitumor
immune response, naïve CD4 T cells need to recognize peptide
antigens presented in an immunogenic context with HLA class II
molecules on activated DCs. Additional co-stimulatory signals,
such as DC-derived cytokines, then promote their differentia-
tion into effector CD4 Th cell subsets characterized by distinct
cytokine secreting profiles (O’Shea and Paul, 2010; Zhu et al.,
2010). The best characterized of these effector cell subsets are the
Th1 and Th2 cells, which are characterized by their production
of IFN-γ and interleukin-4 (IL-4), respectively. More recently, the
pro-inflammatory Th9 and Th17 cell subsets have also been shown
to develop and/or reside in some tumors, along with TReg cells
which are responsible for immune regulation and tissue homeosta-
sis. Following recognition of a specific tumor-associated antigen
presented by an appropriately activated APC, naïve CD4 T cells
undergo several rounds of division and can become polarized
into such distinct effector Th cell subsets that can differentially
orchestrate antitumor immune responses, in part, through their
production of signature cytokines. The differentiation of polarized
CD4 effector T cells is controlled by unique sets of transcription
factors, the expression of which is determined by multiple signals,
in particular, by soluble factors that act on responding CD4 T cells
during their activation. Subsequently, such differentiation results
in distinct Th cell subsets characterized, in part, by select cytokine
production that can initiate, facilitate, and influence distinct mech-
anistic arms of the immune response to tumors as determined in
several murine tumor models as well as in evidence obtained from
human studies. Although the production, function, and mech-
anistic interplay of these signature cytokines derived from the
distinct Th cell subsets will be discussed in more detail below,
it is becoming increasingly clear that considerable plasticity exists
among the various subsets in vivo, especially during responses
to tumors at various stages of development, progression, and/or
regression. Moreover, certain cytokines such as IL-10, can be pro-
duced by nearly all subpopulations of cells within the multiple
effector cell subsets further suggesting, that CD4 T cell responses
are apparently convoluted and capable of initiating and maintain-
ing quantitatively and qualitatively variable antitumor responses
involved in facilitating either direct or indirect tumor cell killing
or survival.
The CD4+ T cell represents a major component of the adap-
tive immune response and has been shown to be an integral part
in the activation and regulation processes of the host response to
many pathogens. Although the role of CD4 T cells in the anti-
tumor response remains under investigated, it is becoming clear
that effective immune responses to a developing or progressing
tumor requires their activation, maturation, and active participa-
tion (Pardoll and Topalian, 1998; Blattman and Greenberg, 2004;
Kennedy and Celis, 2008; Muranski and Restifo, 2009). As one
of their primary emerging roles as “regulators” of the immune
response to cancer, CD4 T cells have been shown to orchestrate and
coordinate many facets of both the innate and adaptive immune
responses to ensure optimal responses by other lymphocytes. CD4
T cells are necessary elements for priming tumor-specific CD8
T cells, influencing the differentiation and expansion of tumor
antigen-specific CTLs and are essential for generating and main-
taining long-term CD8 memory T cell responses (Janssen et al.,
2003; Shedlock and Shen, 2003; Sun and Bevan, 2003; Sun et al.,
2004). Moreover, several studies have defined additional roles for
CD4 T cells, some of which are independent of other lympho-
cytes, that influence and/or contribute to tumor immunity during
carcinogenesis. Paradoxically, several experimental and clinical
observations have recently shown that these same CD4 effector
cell subsets and their signature cytokines can not only contribute
to antitumor responses but also tumor-promoting activities. We
discuss what is known about the T cell subsets that develop dur-
ing different stages of tumor growth and progression, how such
diverse T cell subset responses contribute to disease progression
and/or regression, their development into memory cells, and their
potentials in cancer treatment.
CD4 EFFECTOR T CELL SUBSETS
The roles of polarized CD4 T cell subsets in the antitumor immune
response are greatly influenced by their signature cytokines which
arm the cells with distinct immunological functions. Such cellular
polarization processes are dependent, in part, on their expression
of specific transcription factors that are influenced by multiple cel-
lular and soluble biological signals within the priming milieu of the
tumor environment. Moreover, substantial proportions of effec-
tor T cell subsets that are found in vivo are often characterized by
plasticity and heterogeneity in terms of their cytokine-producing
potentials. Thus effective tumor immunity is often dependent
on such complex CD4 T cell responses following polarization
and their interactions with other Th cell subsets within the hos-
tile tumor environment. In any instance, the most characterized
CD4 Th cell subset is the Th1 that can potentially produce large
amounts of IFN-γ upon tumor antigen encounter and expresses
the transcription factor T-bet. The Th1 developmental pathway
is typically driven by IL-12 activation of the signal transducer
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and activator of transcription 4 (STAT 4) and T-bet transcription
factors during immune activation of naïve T cells (Szabo et al.,
2000, 2003). As the “critical regulator” of the Th1 differentiation
program, T-bet is responsible for the up-regulation of the IL-12
receptor β2 (IL-12β2R) subunit and confers IL-12 responsiveness
and sustained T-bet expression (Lazarevic and Glimcher, 2011).
In addition, it induces and upregulates IFN-γ (ifnγ) production
but also induces the expression of genes encoding the chemokine
receptor CXCR3 and the chemokines CCL3 and CCL4 (Jenner
et al., 2009) which are responsible for enhancing the mobilization
of select type 1-related immune cell responses to sites of tumor
growth. In addition, T-bet suppresses commitment to the Th2
and Th17 lineage programs (Hwang et al., 2005). Although IFN-γ
is considered the signature cytokine for this subset in both murine
and human effector T cells, other cytokines have been shown to be
produced by human Th1 cells and include IL-2, TNF-α, and IL-10.
Interestingly, the importance of IL-10 production by Th1 effector
cell subpopulations in the antitumor response is controversial.
Several recent studies have suggested that IL-10 plays a role in
inhibiting tumor development, growth, and metastases (Mocellin
et al., 2005; Emmerich et al., 2012; Tanikawa et al., 2012). Whereas
others have suggested that Th1 effector cell responses are auto-
regulated through a negative feedback loop via the co-induction
and expression of IL-10 (Cope et al., 2011). Conceivably, the rel-
ative amounts and/or duration of IFN-γ and IL-10 produced
by such double-positive cytokine secreting Th1 cell subsets and
their ability for “cytokine switching” might define the inflamma-
tory/immune response, tolerance induction, and/or prevention of
excessive immunopathology within the tumor microenvironment.
Th2 effector cell subsets are characterized by the production of
IL-4, IL-5, and IL-13 and are responsible for coordinating humoral
immunity and allergic inflammatory responses. IL-4 is primarily
accountable for the differentiation of Th2 cells through STAT 6
and the transcription factor GATA-3 (Kaplan et al., 1996; Zheng
and Flavell, 1997; Kurata et al., 1999; Zhu et al., 2001). The Th1 and
Th2 developmental pathways among naïve CD4 T cells are con-
trolled by a delicate balance of positive feedback loops, as IFN-γ
enhances further Th1 development and IL-4 supports continued
Th2 differentiation. At the same time, cross regulation by IFN-γ
and IL-4 suppresses Th2 and Th1 differentiation, respectively. In
a murine lung metastases model, Th2 effector cells have shown
some indirect antitumor activity through the eosinophil chemo-
tactic factor, eotaxin and eosinophil tumor infiltration (Mattes
et al., 2003). However, the role of Th2 effector cells in the anti-
tumor immune response remains unclear with several studies
suggesting that such CD4 effector cells are associated with car-
cinogenesis and tumor progression (Tatsumi et al., 2002; Ochi
et al., 2012). Recent investigations have shown that in addition to
IL-10, which is essentially produced by all Th cell subsets, a sub-
population within the Th2 subset can preferentially co-produce
IL-24 (a unique member of the IL-10 cytokine family) (Schaefer
et al., 2001; Ouyang et al., 2011). Although its detailed regula-
tion in Th2 cells is currently unclear, IL-24 has been shown to
lack immune repressive functions, suppress human ovarian can-
cer cell growth both in vitro and in vivo, and induce substantial
“bystander antitumor” immunity in patients (Fisher, 2005; Lebe-
deva et al., 2007; Emdad et al., 2009; Dash et al., 2010). Further
investigation into understanding the development and properties
of IL-24-secreting Th2 cells may provide profound therapeutic
benefits for cancer patients.
The expression of IL-17 characterizes a subset of CD4 helper
T cells (Th17). This cell lineage represents a third effector arm
of CD4-mediated immune response and complements, in part,
the functions of the Th1 and Th2 cell lineages. In addition to IL-
17A and IL-17F, human Th17 cells also produce other cytokines
such as IL-21, IL-22, and IL-26. In addition, the chemokine recep-
tor CCR6 [which binds to the chemokine CC ligand 20 (CCL20)
that is present in many malignant pleural effusions of lung cancer
patients] is highly expressed on Th17 cells thus further facilitat-
ing their recruitment to sites of tumor growth and inflammation
(Acosta-Rodriguez et al., 2007; Annunziato et al., 2007, 2012). Both
human and murine Th17 cells express the transcription factors
retinoic acid orphan receptor (ROR)γt (Rorc). ROR-γt is a critical
regulator of Th17 cell differentiation and induces IL-17A, IL-17F,
IL-26, and CCR6 expression while downregulating IFN-γ produc-
tion in human naïve T cells (Manel et al., 2008). For induction and
differentiation of murine Th17 cells, TGF-β and IL-6 are the most
crucial cytokines for naïve CD4 cell differentiation (Murugaiyan
and Saha, 2009; Gaffen, 2011). However, in the development of
human Th17 cells, it has been shown that IL-6 and IL-1β, but
not TGF-β, is essential for differentiation (Acosta-Rodriguez et al.,
2007; Wilson et al., 2007). In any instance, IL-21 produced by Th17
cells further amplify Th17 generation in an autocrine manner and
induce IL-23 receptor expression that enables cell responses to
IL-23 stimulation. Subsequently, DC-derived IL-23 stabilizes the
Th17 phenotype and helps Th17 cells to acquire effector func-
tions. The induction of ROR-γt is dependent on STAT-3, which is
preferentially activated by IL-6, IL-21, and IL-23. STAT-3 affects
ROR-γt expression and binds to the IL-17 and IL-21 promoters.
Thus, both STAT-3 and ROR-γt transcription factors regulate IL-
17 production in a highly coordinated manner (Murugaiyan and
Saha, 2009). In addition to characterizing Th17 cells by transcrip-
tion factors and cytokine production, recent studies have shown
that human Th17 cells originate from a CD4 precursor cell pop-
ulation that is present in both thymus and umbilical cord blood
and co-expresses a member of the NK cell receptor-P1 family,
CD161 (Cosmi et al., 2008). Although the precise function of
CD161 is unknown at this time, it is considered a “hallmark” of
human memory Th17 cells at sites of tissue inflammation (Cosmi
et al., 2008; Kleinschek et al., 2009). Another marker that was
identified to be specifically associated with human Th17 cells is
the IL-4-induced gene 1 (IL-4I1) which encodes the enzyme l-
phenylalanine oxidase. This enzyme is responsible, in part, for
H2O2 production that can contribute to the inhibition of T lym-
phocyte proliferation (Boulland et al., 2007). As will be discussed
below, Th17 cells are found in several human tumors. Although
Th17-associated cytokines have been linked with carcinogenesis
and tumor progression within the context of chronic inflamma-
tion and infection, it is becoming clear that this cell lineage can
also contribute to the antitumor response in human malignancies
of epithelial origin (Kryczek et al., 2007, 2009a; Zou and Restifo,
2010; Wilke et al., 2011).
Th22 CD4 T cells, which are thought to be a distinct Th subset
that produce IL-22 independently of IL-17, were initially identified
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in patients with inflammatory disorders of the skin, intestine, and
joints (Eyerich et al., 2009; Sonnenberg et al., 2011). More recently,
such cells have also been identified and suggested to contribute to
immune responses and inflammation in malignant pleural effu-
sions and other human cancers (Zhang et al., 2008; Jiang et al.,
2011; Miyagaki et al., 2011; Ye et al., 2012). Such Th22 cells express
the cutaneous lymphocyte antigen (CLA), a functional E-selectin
ligand that is involved in lymphocyte rolling on the endothelial
cells of cutaneous postcapillary venules, along with the chemokine
receptors CCR6, CCR4, and CCR10 which together facilitate the
constitutive migration potentials of these cells to sites of inflam-
mation (Duhen et al., 2009). Although the role, if any, of Th22 cells
in the antitumor immune response is unclear, it is believed that
such IL-22 producing CD4 Th cells contribute to local immune
homeostasis and inflammation (Duhen et al., 2009).
The latest addition to the list of subsets, termed Th9, secretes
IL-9 as the signature cytokine and may play a role in several
inflammatory disorders. Naïve human and murine CD4 T cells
both acquire a Th9 phenotype in vitro with the combination of
IL-4 and TGF-β (Houssiau et al., 1995; Veldhoen et al., 2008;
Beriou et al., 2010; Chang et al., 2010; Putheti et al., 2010; Yao
et al., 2011; Jabeen and Kaplan, 2012; Wilhelm et al., 2012).
The transcription factors STAT6, interferon regulatory factor 4
(IRF4), and PU.1 contribute to Th9 differentiation (Jabeen and
Kaplan, 2012). IL-4-activated STAT6 promotes expression of IRF4
whereas PU.1 activation occurs downstream of TGF-β signal-
ing where it directly bind to the IL-9 (il9) promoter (Chang
et al., 2005, 2009, 2010). Interestingly, polarized Th2 cells can
be deviated into Th9 cells by exposure to TGF-β, which results
in down-regulation of GATA-3 and loss of IL-4 and IL-5 pro-
duction. Using various gene knockout and transgenic mouse
systems, Th9 cells have been shown to contribute to autoim-
mune and allergic inflammation processes (Noelle and Nowak,
2009). However, one recent study identified Th9 cells in healthy
human blood and skin and also in metastatic lesions of patients
with stage IV melanoma (Purwar et al., 2012). Moreover, using a
murine tumor model, these same investigators showed that adop-
tive transfer of tumor-reactive Th9 cells and administration of
recombinant IL-9 can effectively reduce melanoma growth. This
evidence from a single study suggests that IL-9 producing Th9
cells may play a role in the generation of effective antitumor
responses.
The final CD4 Th cell lineage to be described here resides in
proximity to B cells within germinal centers of lymphoid tis-
sues. These cells, referred to as follicular helper T cells (TFH),
are responsible for providing B cell help and supporting B cell
expansion and differentiation (Reinhardt et al., 2009; Ma et al.,
2012). They are defined by expression of the transcription fac-
tor Bcl6 and the cytokines IL-21 (Liu et al., 2012b). Moreover,
they express the chemokine receptor CXCR5 which facilitates
migration to the B cell follicles after activation (Chtanova et al.,
2004; Haynes et al., 2007). Studies have also shown that they
possess key surface receptor molecules (PD-1, CD40 ligand, OX-
40, CD84, and ICOS) that play critical roles in promoting B cell
activation, differentiation, and survival (Ma et al., 2012). However,
the role of TFH cells in tumor immunity remains relatively
undefined.
Accumulating evidence suggests that select CD4 effector T cell
subsets may have a more “direct” role in inhibiting tumor growth
and progression that are independent of their more “indirect”
helper activities. As such, CD4 effector T cells have, in general,
been shown to protect against both tumors and virally infected
target cells through two distinct primary effector mechanisms.
They include the production of cytokines, most notably IFN-γ
and TNF (Hung et al., 1998; Pardoll and Topalian, 1998) and
through direct cytolytic activity (Trapani and Smyth, 2002) that is
mediated by degranulation of cytotoxic granules containing toxic
effector molecules (i.e., perforin and granzyme) or ligation of
the Fas (also known as CD95)/Fas Ligand (FasL; also known as
CD95L) apoptotic killing pathway (Green and Ferguson, 2001).
Cytolytic CD4 T cells possessing such cytotoxic activity have been
described in peripheral blood of both healthy and virally infected
individuals (Feighery and Stastny, 1979; Appay et al., 2002; van
Leeuwen et al., 2004; Casazza et al., 2006; Stuller and Flano, 2009;
Nemes et al., 2010; Stuller et al., 2010). Phenotypic analysis has
shown that they are CD45RO+, CCR7−, CD27−, and CD28− and
shown to possess high levels of the cytolytic effector molecules
granzyme A, granzyme B and perforin (Appay et al., 2002; Casazza
et al., 2006) suggesting that these cells are antigen-experienced
and terminally differentiated CD4 effector cells. Moreover, as with
CD8 effector T cells (Pearce et al., 2003; Intlekofer et al., 2005),
there is evidence that expression of the eomesodermin (Eomes)
transcription factor may be crucial in driving the development
of cytotoxic CD4 T cells in vivo (Qui et al., 2011; Hirschhorn-
Cymerman et al., 2012). Although T cell expression of eomeso-
dermin has been linked to terminal differentiation and memory
cell phenotype with the concomitant secretion of Th1 cytokines
(Hirschhorn-Cymerman et al., 2012), others have suggested that
cytotoxic activity of CD4 effector T cells does not depend on
Th1 cell polarization (Brown et al., 2009). Thus suggesting that
such cells constitute a unique and separate cell lineage from those
already described. In either instance, more recent studies using a
murine transgenic tumor model of advanced melanoma, showed
that transfer of naïve tumor-reactive CD4 T cells into lymphopenic
recipients can induce a substantial expansion and differentiation
of Th1 cells with cytotoxic activity (Quezada et al., 2010; Xie et al.,
2010). Moreover, induction of such cells correlated with class II-
restricted tumor rejection that was dependent on the presence of
IFN-γ which was believed to mediate the up-regulation of class II
on tumor target cells. In more recent studies using both human and
murine cells, generation of tumor-reactive cytotoxic CD4 Th1 cells
were further shown to be induced, in part, by both the engagement
of a specific co-stimulatory pathway of the tumor necrosis factor
receptor (TNFR) family member, OX-40 (also known as CD134)
and an intracellular mechanism relying on eomesodermin expres-
sion (Qui et al., 2011; Hirschhorn-Cymerman et al., 2012). Further
identification and characterization of the mechanisms involved in
the induction of tumor-reactive CD4 T cells with cytotoxic activ-
ities in cancer patients may offer significant advantages for future
treatment strategies of human malignancies.
Lastly, the subpopulations of CD4+ TReg cells can be classified
into two main subsets according to their origin and suppressive
activity. Natural CD4+ TReg effector cells (nTRegs), constitu-
tively expressing FoxP3 and the activation marker CD25, originate
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in the thymus by high affinity interaction of the T cell receptor
(TCR) with Ag expressed on the thymic stroma (Sakaguchi, 2008;
Shevach, 2009; Buckner, 2010; Nishikawa and Sakaguchi, 2010;
Sakaguchi et al., 2010; Miyara and Sakaguchi,2011). Such cells sup-
press the proliferation of effector T cells in a contact-dependent,
cytokine-independent manner. In contrast, other types of TReg
cells can be induced from naive CD4 cells in the periphery, such as
IL-10-producing TR1 cells and TGF-β-producing Th3 cells (Groux
et al., 1997; O’Garra et al., 2004; Grazia-Roncarolo et al., 2006;
Nishikawa and Sakaguchi, 2010). Such “induced” CD4+CD25−
TReg subpopulations (iTReg) exert suppression mostly through
soluble factors and their suppressive function is not strictly associ-
ated with a high level of FoxP3 expression. Moreover, human TReg
cell subpopulations have also been further divided into two sub-
sets based on their expression of the “resting” CD45RA (a marker
of naïve or antigen-inexperienced cells) or “activated” CD45RO
(a marker for memory or antigen-experienced T cells) cell sur-
face markers (Vukmanovic-Stejic et al., 2006; Miyara et al., 2009;
Miyara and Sakaguchi, 2011; Duhen et al., 2012) further suggesting
different levels of activation and/or differentiation among these
CD4 subsets. More recently, another inducible subpopulation of
the CD4+ TReg cell subset have been reported in both human
and murine systems that involve production of IL-35 and are thus
referred to as iTreg35 cells (Collison et al., 2010; Chaturvedi et al.,
2011). Notably, these cells are phenotypically and functionally dis-
tinct from other subpopulations of TReg cells described thus far
in that they do not express FoxP3 and they mediate immunosup-
pression via IL-35 and seemingly independent of IL-10, TGF-β,
the immunomodulatory receptor CTLA-4, or any other currently
known TReg cell-associated suppressive molecule. Although it
seems that human nTReg cells do not express IL-35 (Bardel et al.,
2008), naïve human CD4 T cells can be induced to develop into
iTReg35 cells in the presence of IL-35 or activated DCs (Collison
et al., 2010; Seyerl et al., 2010). Alternatively, it has been sug-
gested that human TReg subpopulations can be further classified
by their expression of select chemokine receptors that corre-
spond to Th cell lineage-specific immune responses (Duhen et al.,
2012). For example, TReg subpopulations co-expressing CCR6
(Th17-associated responses), CXCR3 (Th1-associated responses),
CCR4 (Th2-associated responses), and CCR10 (Th22-associated
responses) enable human TReg cell subpopulations with unique
specificities and immunomodulatory functions to target defined
immune environments during different types of inflammatory
responses so as to exert an “appropriate” regulatory process. Thus,
suggesting that Th and TReg cells undergo functional special-
ization in parallel, resulting in the development of TReg cell
subpopulations capable of co-localizing and effectively regulating
different types of Th cell responses in vivo (Hall et al., 2011; Duhen
et al., 2012). In any instance, the precise mechanisms by which
these various subpopulations of TReg cells function to maintain
the balance between protective tumor immunity and establishing
or rebalancing immune cell homeostasis remains poorly under-
stood. However, several mechanisms responsible for preventing
inflammatory disease by restraining aberrant responses to self or
innocuous antigens have been identified (Vignali et al., 2008; She-
vach, 2009; Qureshi et al., 2011; Yamaguchi et al., 2011; Vignali,
2012; Wing and Sakaguchi, 2012). These include both cell contact
and soluble factor-dependent mechanisms, such as production
of IL-10; the production and surface expression of TGF-β; the
production of IL-35; the release of cytolytic molecules such as
granzyme and perforin; the consumption of IL-2 through the high
density expression of cell surface CD25 (the alpha chain of the IL-2
receptor) which weans effector T cells from IL-2; the degradation
of ATP through ectonucleotidases; and expression of the inhibitory
receptors CTLA-4, which outcompetes receptor CD28 on effector
T cells for access to the co-stimulatory molecules CD80 and CD86
on APCs.
CD4 MEMORY T CELL DEVELOPMENT AND THEIR ROLE IN
THE ANTITUMOR RESPONSE
During the antitumor response a small population of tumor-
specific CD4 effector T cells may develop into memory T cells
that retain their previous effector functions and rapidly produce
effector cytokines (McKinstry et al., 2010; Taylor and Jenkins,
2011; Strutt et al., 2012). Their ability to remember previously
encountered antigens leads to faster responses to tumor anti-
gen re-exposure and thus may play a role in preventing disease
relapse in cancer patients. Alternatively, as discussed earlier, it can
shape tumor cell immunogenicity and modulate immune response
dynamics to influence disease progression (Schreiber et al., 2011;
Vesely et al., 2011). In humans,different isoforms of the CD45 mol-
ecule are often used to differentiate naïve and memory cells with
the former expressing CD45RA and the latter expressing CD45RO
(Ahmed and Gray, 1996). Increased expression of other surface
molecules such as the CD95 death receptor has also been shown
to differentiate memory cells from naïve CD4 T cells. Moreover,
memory T cells have been divided into two general subgroups
based on their patterns of migration (Sallusto et al., 1999). Cen-
tral memory T cells (TCM) express the CC-chemokine receptor
CCR7 and L-selectin CD62L following activation. Expression of
these receptors enable the TCM subgroup to recirculate through
secondary lymphoid organs such as lymph nodes. Such circula-
tion is beneficial since DCs from diverse tissue sites continuously
bring antigen to the draining lymph nodes, thereby increasing the
effective area of memory cell immunosurveillance for progress-
ing tumor growth due to metastases and/or occult cell outgrowth.
Alternatively, effector memory T cells (TEM) lack expression of
CCR7 or CD62L and thus have a propensity to migrate to periph-
eral tissues in response to localized inflammatory stimuli and
bolster the process of immune surveillance at such sites. More-
over, expression of other surface chemokine receptors such as
CCR5 have been associated with polarized Th1 memory T cell
subsets (Loetscher et al., 1998; Sallusto et al., 1998; Kim et al.,
2001; Luther and Cyster, 2001; Charo and Ransohoff, 2006). In
either instance, retention and tissue tropism of memory CD4 T
cell subsets and their diverse functional capacities are dependent,
in part, on specific interactions between adhesion molecules and
effector cell chemokine receptors that induce T cell subset localiza-
tion and influence tumor environments. This has been shown in
studies with cancer patients where increased intratumoral mem-
ory T cell levels were associated with longer disease free and overall
survival rates (Pagès et al., 2005; Bindea et al., 2010). In another
study involving colon cancer patients, histopathological analysis
showed the presence of “patches”of TEM cells located within either
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the center or invasive margins of the tumor that further correlated
with good clinical outcome (Galon et al., 2006). These investigators
suggested that memory cell localization at select regions within the
tumor mass may be associated with not only enhanced antitumor
immune responses but also effective control of metastatic escape.
However, as briefly mentioned earlier, such observations and effec-
tive antitumor responses may not only depend on memory cell
phenotype and localization, but also their functional memory pre-
cursor phenotype and ability for “cellular plasticity” within the
hostile tumor environment.
In addition to surface markers, differential expression levels of
select transcription factors have been associated with promoting
effector and memory T cell development. In studies using vari-
ous genetically modified mouse strains, investigators have shown
that under conditions of inflammation, elevated levels of the tran-
scription factor T-bet (Tbx21) among responding CD8 T cells
promoted the generation of terminally differentiated short-lived
effector cells whereas lower levels facilitated long-lived, self renew-
ing memory T cell development (Joshi et al., 2005; Lazarevic and
Glimcher, 2011). In more recent studies, it was shown that IL-12
augmented activity of the kinase mammalian target of ramamycin
(mTOR) (Rao et al., 2010; Cox et al., 2011) which is essential for
sustained T-bet expression and the generation of effector CD8
T cells. Subsequently, inhibition of mTOR activity blocked T-
bet expression and promoted elevated and sustained levels of the
closely related T-bet transcription factor eomesodermin (Eomes)
that is associated with the development of memory T cells (Pearce
et al., 2003; Intlekofer et al., 2005, 2008; Joshi et al., 2005; Rao
et al., 2010). Moreover, over-expression of eomesodermin or T-
bet has been shown to be sufficient to induce expression of IFN-γ,
perforin, and granzyme B in CD8 T cells (Pearce et al., 2003; Cruz-
Guilloty et al., 2009). Thus suggesting that (i) the transcription
factors T-bet and eomesodermin have cooperative and partially
redundant functions in CD8 T cell differentiation and fate (Rao
et al., 2010) and (ii) the balance between the two transcription
factors, as “instructed” by mTOR kinase activity, can determine
the CD8 effector cell fate verses memory cell fate (Araki et al.,
2009; Rao et al., 2010). Although the transition of CD4 effec-
tor to memory T cell phenotype is less defined, evidence using
a murine viral infection model has shown a similar correlation
with decreased T-bet (Tbx21) expression levels and potential Th1
memory cell development (Marshall et al., 2011). Furthermore,
in a mouse model of allergic airway inflammation, IL-5 produc-
tion among a Th2 memory cell subpopulation was shown to be
uniquely regulated by the expression of eomesodermin (Eomes)
suggesting a role for this transcription factor in the regulation of
polarized CD4 T cell functions (Endo et al., 2011). Whereas, in a
study using peripheral blood from healthy human donors, expres-
sion of T-bet was shown to be up-regulated among specific Th1
memory cell subpopulations following TCR stimulation whereas
elevated expression levels of eomesodermin (Eomes) were asso-
ciated with a higher level of IFN-γ production during the recall
response in a corresponding cell subpopulation (Narayanan et al.,
2010). Lastly, similar results were observed in the murine system
suggesting a role for Eomesodermin (Eomes) in the development
of Th1 cell differentiation and memory phenotype under various
stimulating conditions ex vivo (Suto et al., 2006; Yang et al., 2008;
Hirschhorn-Cymerman et al., 2012). Collectively, it is unclear
which responding CD4 effector T cells make the transition to a
memory phenotype, but these recent studies suggest that differ-
ential expression levels and balance between transcription factors
promote and/or facilitate the T cells potential to do so. In either
instance, this “phenotypic progression” from effector to memory
T cell provides a qualitative advantage in the antigen-specific anti-
tumor response by enhancing immune response time, the need
for less co-simulation and more vigorous proliferation especially
at lower levels of tumor antigen exposure when compared to that
of antigen-inexperienced T cells.
HELPER FUNCTIONS AND THE POTENTIALLY “GOOD” AND
“BAD” SIDES OF CD4 EFFECTOR T CELL SUBSETS IN THE
ANTITUMOR IMMUNE RESPONSE
Although the best studied pathways of CD4 T cell-mediated help
are those that promote antibody production by B cells, such cells
also enhance tumor-specific CD8 T cell responses during disease
progression and contribute to the maintenance of a functional
memory CD8 T cell pool (Pardoll and Topalian, 1998). Various
CD4 T cell subsets can also alter the function of APCs (especially
DCs) and innate immune cells (Hung et al., 1998). In addition
to enhancing and/or regulating T cell-mediated responses, that
include both promoting long-term immunity and establishing or
rebalancing immune cell homeostasis, CD4 T cells can also have
a direct role in tumor elimination (Pardoll and Topalian, 1998;
Quezada et al., 2010; Xie et al., 2010). Paradoxically, several exper-
imental and clinical observations have recently shown that such
CD4 effector cell subsets and their signature cytokines can not
only contribute to effective antitumor responses but also facili-
tate tumor-promoting activities. In this section of the review, we
will discuss these points and focus on the three most studied and
potentially most promising CD4 effector T cell subsets involved
in antitumor immunity and therapy, namely the Th1, Th17, and
TReg cell subsets.
THE TH1 AND IFN-γ PARADOX
Th1 cells are potent inducers of cell-mediated immunity and
inflammation. Through studies using various murine tumor mod-
els, Th1-mediated immune responses have been shown to partic-
ipate and facilitate in the elimination of established tumors and
reduce tumor development and susceptibility to carcinogenesis.
Moreover, it has been observed in studies of patients with vari-
ous cancer types that favorable clinical outcomes, as assessed by
disease free and overall survival, can be attributed to an enhanced
and coordinated Th1 effector cell infiltration within the tumors
of these patients (Fridman et al., 2011). IFN-γ is produced pre-
dominantly by the Th1 CD4 effector T cell subset. Tumor antigen-
specific Th1 cells control tumors, in part, through the secretion of
IFN-γ that can have both direct and indirect effects on immune
activation and modulation (Mumberg et al., 1999; Zaidi and Mer-
lino, 2011). IFN-γ derived from Th1 cells can induce a cascade
of events involving the priming and maturation of cytolytic CD8
T cells through activation of DCs at the sites of tumor growth
and further induce tumor elimination through activation of NK
cells and type 1 macrophages (Corthay et al., 2005; Quezada et al.,
2010; Palucka and Banchereau, 2012). Moreover, IFN-γ can induce
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development of the Th1 cell lineage, rather than the potentially
tumor-promoting Th2 lineage, and further promote expression of
the chemokine receptor CXCR3 and its ligands CXCL9, CXCL10,
and CXCL11 that can specifically attract and enhance Th1 cell
localization to sites of tumor growth and inflammation (Rotondi
et al., 2003). Other studies have suggested that IFN-γ actually
inhibits the generation and/or activation of naturally occurring
TReg cell subsets (Nishikawa et al., 2005; Caretto et al., 2010).
Similarly, another group showed IFN-γ signaling caused cell cycle
arrest in TReg cells suggesting that this IFN-γ-dependent mecha-
nism could counteract the ability of TReg cells to protect tumors
in cancer patients (Cao et al., 2009). Aside from its immune stimu-
latory roles and affects on various T cell subpopulation dynamics,
IFN-γ can up-regulate HLA class I and class II molecules on tumor
cell populations that aid in facilitating cytolytic T cell recognition
and elimination of tumors. Studies in both human and murine
systems have shown IFN-γ to inhibit cancer cell proliferation
(Bromberg et al., 1996; Chin et al., 1996; Hobeika et al., 1999;
Platanias et al., 1999; Zaidi and Merlino, 2011), promote tumor
cell apoptosis through effects on the expression of caspases, FAS
(also known as CD95), and TRAIL (Takeda et al., 2002; Chin et al.,
1997; Xu et al., 1998; Meng and El-Deiry, 2001), and inhibit angio-
genesis within the tumor environment (Luster and Leder, 1993;
Coughlin et al., 1998; Ruegg et al., 1998. Beatty and Paterson,
2001). With respect to angiogenesis, IFN-γ is a potent inducer
of several angiostatic chemokines, such as CXCL9 and CXCL10,
from a variety of cells, including monocytes, macrophages, fibrob-
lasts, endothelial cells, and tumor cells (Luster and Ravetch, 1987;
Farber, 1990; Arenberg et al., 1996; Cole et al., 1998). This may
contribute to a shift the local biologic balance between angiogenic
and angiostatic chemokines that results in anti-angiogenesis and
tumor-associated vascular inhibition. Of course, the different IFN-
γ-inducible processes and effects, that are responsible for directly
limiting tumor growth and progression, are not only dependent
on tumor type, but also cytokine concentration and expression of
the extracellular domains of the IFN-γ receptor subunits and their
intracellular signaling transmission pathways among the various
cells within a dynamic tumor environment (Ealick et al., 1991;
Boehm et al., 1997).
Alternatively, a dual role for IFN-γ in the context of malignancy
has been reported and associated with contributing to enhanced
tumor growth and metastases (Dunn et al., 2006; Schreiber et al.,
2011). Several reports have suggested that IFN-γ, possibly derived
from Th1 cells, can up-regulate the surface expression of the
immunoinhibitory molecule B7-H1 on tumor-associated APCs
(Dong et al., 2002; Liu et al., 2007; Zou and Chen, 2008; Wu
et al., 2009a; Kondo et al., 2010). Under such conditions, cross-
talk between these APCs and T cell expressing the correspond-
ing ligand, PD-1, could result in a coordinated suppressive and
tolerogenic environment. In addition, it has been shown that
T cell-derived IFN-γ can interact with tumor cells and tumor-
associated APC to induce the expression of indoleamine 2,3-
dioxygenase (IDO), an enzyme that degrades the essential amino
acid tryptophan that leads to the suppression of T cell immunity
(Carlin et al., 1987; Munn et al., 2002; Fallarino et al., 2003; Zou,
2005; Sharma et al., 2007; Mellor and Munn, 2008; Muller et al.,
2008). It has been shown that IFN-γ can enhance the presence of
myeloid-derived suppressor cells (MDSC), in an IFN-γ-dependent
manner, within the tumor microenvironment resulting in the sup-
pression of T cell responses (Ostrand-Rosenberg and Sinha, 2009;
Gabrilovich et al., 2012). Lastly, it has been reported that IFN-
γ can facilitate and/or mediate either contraction of the CD4 T
cell population via induction of apoptosis (Berner et al., 2007) or
up-regulate and induce the development of TReg cells (Agnello
et al., 2003; Liu et al., 2009; Campbell and Koch, 2011). Such
IFN-γ-mediated activity derived from Th1 cells infiltrating sites of
tumor growth can conceivably undermine the antitumor immune
response by negatively affecting T cell population dynamics in vivo.
For example, Th1 cells may possess homeostatic functions under
select conditions within the tumor that can influence the gener-
ation, survival and balance of CD4 and CD8 effector and mem-
ory T cell subpopulation pools necessary for effective antitumor
responses. Consequently, such immune-mediated effects on the
local tumor environment could be responsible for the promo-
tion of tumor cell dormancy and contribute to the maintenance,
potential progression and/or re-emergence of occult tumor cells
or cancer-related stem cells (Mellor and Munn, 2008; Schreiber
et al., 2011).
Finally, with regards to clinical application, recombinant IFN-
γ was initially used to treat chronic myelogenous leukemia, alone
and in combination with IFN-α, but failed to show any signifi-
cant positive outcome (Kurzrock et al., 1987; Kloke et al., 1992).
Since then, recombinant IFN-γ has been used in the clinical
management of a variety of malignancies including bladder carci-
noma, colorectal cancer, ovarian cancer, and adult T cell leukemia;
however, the results have been mixed (Miller et al., 2009). In
melanoma patients, early small scale clinical trials were largely
inconclusive (Creagan et al., 1987; Ernstoff et al., 1987; Kowalz-
ick et al., 1990; Kopp et al., 1993). In another trial for adjuvant
application in patients with melanoma, studies were prematurely
terminated due to the observations that IFN-γ-treated patients
fared worse than the untreated population (Meyskens et al., 1990,
1995). Although the clinical application and therapeutic effects
of directly administered recombinant IFN-γ in cancer patients
appears marginal, there is limited experience in investigations
focused on therapies utilizing direct transfer of tumor-reactive
CD4 T cells secreting IFN-γ. Several earlier clinical studies uti-
lizing various T cell transfer therapies have suggested that the
incorporation of CD4 T cells would heighten therapeutic efficacy
and improve clinical outcome (Walter et al., 1995; Dudley et al.,
2002; Ho et al., 2002; Levine et al., 2002; Kershaw et al., 2006;
Bollard et al., 2007). One of the initial clinical studies showing
autologous IFN-γ producing CD4 T cell transfer as an effective
therapeutic agent in cancer patients was performed by Hunder
et al. Using an autologous CD4 T cell clone with specificity to
the melanoma-associated antigen NY-ESO-1, these investigators
showed that transferred tumor-reactive IFN-γ-producing CD4 T
cells mediated a durable clinical remission and promoted endoge-
nous responses against melanoma antigens other than NY-ESO-
1 in a melanoma patient (Hunder et al., 2008). Furthermore,
the patient experienced a complete response with persistence of
the transferred cells and a concomitant induction of melanoma
antigen-reactive CD8 T cells. In our adoptive T cell therapy
studies with late stage ovarian cancer patients, using peripheral
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blood-derived MUC1 peptide-stimulated Th1-like effector T cells,
we reported that autologous T cell re-stimulation and subse-
quent intra-peritoneal re-infusion modulated endogenous T cell-
mediated immune responses and systemic T cell subpopulation
dynamics that were associated with enhanced patient survival
(Dobrzanski et al., 2011). In spite of the limited numbers of such
studies investigating CD4 T cell based immunotherapy in cancer
patients, it is becoming apparent that Th1 cells possess the capacity
to modulate the immune response and potentially enhance tumor
immunity in the clinical setting.
THE IMMUNOMODULATION PARADOX OF IL-10 DERIVED FROM CD4
EFFECTOR T CELLS
Several studies support the view that IL-10 may diminish the
immune response against cancer by directly inhibiting cell acti-
vation of select human T cell subpopulations (de Waal Malefyt
et al., 1993; Taga et al., 1993; Joss et al., 2000). IL-10 can also
act as a negative mediator in the cross-talk between innate and
adaptive antitumor immunity. For example, it has been reported
that the IL-10 immunosuppressive activity on T cells is mainly
indirect and is functionally linked to other immune cells such
as TReg cells, MDSC, and APCs. In the case of APCs, IL-10
restrains antigen presentation via its inhibition of MHC and co-
stimulatory B7 family member molecules (Vicari and Trinchieri,
2004; O’Garra and Murphy, 2009), stimulates up-regulation of
inhibitory B7 family members (Curiel et al., 2003; Kryczek et al.,
2006; Zou and Chen, 2008), down-regulates IL-12 production, and
inhibits DC maturation and differentiation (Moore et al., 2001).
In vitro studies have shown that T cells can be anergized toward
melanoma-associated antigens when stimulated with IL-10 con-
ditioned DCs (Steinbrink et al., 1999), and DCs which infiltrate
progressing melanoma metastases in humans, have been charac-
terized to express low levels of CD86 and IL-12 but possess an
enhanced capacity to produce IL-10 (Enk et al., 1997). Moreover,
IL-10 producing monocytes and select populations of the myeloid
lineage, which inhibit T cell proliferation, have been isolated from
the ascites of patients with ovarian carcinomas (Loercher et al.,
1999). These cells and their subpopulations, such as MDSCs, can
promote the local clonal expansion and/or induce conversion of
naïve CD4 T cells into TReg cell populations (Gabrilovich et al.,
2012). Moreover, it has been reported that the CD4+ Tr1 reg-
ulatory cells produce antigen-driven IL-10 that is responsible for
peripheral immune tolerance through the impaired activation and
regulation of CTL, Th1, and other effector Th cell subsets that
further facilitate elevated tumor growth through immune escape
mechanisms (Seo et al., 2002). It is now clear that IL-10 can not
only mediates inducible TReg cell immunosuppressive activity but
also plays a direct role in their genesis (Roncarolo et al., 2001).
In vitro studies have shown that IL-10 treatment can convert dif-
ferent types of tumor cells, such as melanoma and lymphoma, to
a CTL-resistant phenotype by decreasing the expression of HLA
class I molecules on their surface (Petersson et al., 1998; Kurte et al.,
2004). Similarly, IL-10 production by human basal and squamous
cell carcinoma prevents in vitro lysis of autologous malignant cells
by cytolytic T lymphocytes (Kim et al., 1995). Lastly, recent studies
have shown that endogenous IL-10 can potentially limit the pro-
tumor and/or antitumor effects of Th17-mediated inflammation
either indirectly by promoting the regulatory functions of both
FoxP3+ and FoxP3− cells or directly by interacting with IL-10
receptors on Th17 cells in an IL-10 signaling-dependent man-
ner (Chaudhry et al., 2011; Huber et al., 2011). Collectively these
studies in both the animal and human systems suggests that IL-10
is involved in both direct and indirect tumor immunosuppressive
networks that can promote and facilitate tumor immune tolerance
resulting in malignant progression.
Although IL-10 is generally regarded as an anti-inflammatory
and immunosuppressive cytokine that favors tumor escape from
immune surveillance, evidence is accumulating that IL-10 also
possesses immunomodulatory properties that support antitumor
immunity. For example, transfection of tumor cells with IL-10
or systemic administration of exogenous IL-10 significantly sup-
pressed tumor growth and led to tumor rejection in several differ-
ent murine tumor models in vivo (Giovarelli et al., 1995; Berman
et al., 1996; Fujii et al., 2001; Mumm et al., 2011). Moreover, such
antitumor effects of IL-10 were dependent on CD8 T cells. In vitro
studies have further shown that IL-10 can induce proliferation and
cytotoxic activity of human CD8 T cells and function as a chemoat-
tractant for CD8 T cells (Chen and Zlotnik, 1991; Jinquan et al.,
1993; Groux et al., 1998; Santin et al., 2000). In more recent stud-
ies using IL-10 and IL-10 receptor knockout and transgenic mouse
strains, investigators reported that IL-10 directly mediated intra-
tumoral activation and expansion of resident tumor-reactive CD8
T cells that independently rejected established tumor growth and
progression (Emmerich et al., 2012). Alternatively, another group
using IL-10 knockout mice showed that IL-10 indirectly hindered
tumor development, growth, and progression by impeding the
development of both MDSCs and CD4+ TReg cells which pre-
sumably contributed to immune suppression, carcinogenesis, and
tumor pathology (Tanikawa et al., 2012). Lastly, recombinant IL-10
has been associated with stimulating pro-inflammatory responses,
such as IFN-γ production, when administered to humans (Lauw
et al., 2000; Tao et al., 2001; Tilg et al., 2002). Since it is clear
that nearly all CD4 effector T cell subsets can potentially pro-
duce IL-10, it is conceivable that endogenous IL-10 (such as IL-10
derived from CD4 helper/effector T cells infiltrating sites of tumor
growth) may exhibits both antitumor and pro-tumor activities
(Mocellin et al., 2001). Under both scenarios, IL-10 may influ-
ence tumor cells through the development, recruitment, and/or
activation of various immune response cells, including tumor-
reactive CD8 and other CD4 effector T cell subsets. Alternatively,
a body of both clinical and pre-clinical data is emerging show-
ing that IL-10 can influence tumor growth and progression by
non-immune-related phenomena such as the inhibition of angio-
genesis and induction of tumor cell apoptosis (Mocellin et al.,
2005). In either instance, the role of endogenous IL-10 as a media-
tor of either tumor escape or successful immune surveillance may
depend upon the conditions of initial carcinogenesis and tumor
type, level of tumor progression, and the presence of responding
immune cell populations at the sites of tumor growth.
Many CD4 Th cell subsets can potentially produce IL-10, as well
as their hallmark cytokines, following engagement of their TCR
with antigen (Sariava and O’Gara, 2010). The presence of reactive
tumor infiltrating CD4 helper T cells have been associated with
good clinical outcomes in patients with select cancer types (Pagès
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et al., 2005). Interestingly, this broaches the possibility that IL-10-
derived from such Th cells may act, in part, as an immunological
adjuvant in the antitumor response to cancer. A subset of Th1 cells
has been identified in both murine and human systems and found
to either stably or transiently produce both IL-10 and IFN-γ dur-
ing periods of chronic inflammation and disease (Jankovic et al.,
2010; Cope et al., 2011). Several signals have been found to stim-
ulate the generation of such dual cytokine-expressing effector cell
subpopulations, including high levels of antigen, soluble factors
such as IL-12 and IL-27, and co-stimulatory signals such as ICOS
(Jankovic et al., 2010). More recently, it has been suggested that
such cytokine switching and/or co-expression in both human and
mouse cells of the Th1 lineage may be linked to the role of the com-
plement regulator and T cell co-stimulatory molecule, CD46 with
the addition of either TCR engagement or high amounts of IL-12
(Meyaard et al., 1996; Cardone et al., 2010). In either instance, it has
been suggested that Th1 effector cell responses are auto-regulated
through not only extrinsic but also intrinsic negative feedback
loops via the co-induction of IL-10 and IFN-γ. Thus, it is conceiv-
able that the relative amounts and/or duration of IFN-γ and IL-10
produced by such double-positive cytokine secreting effector cell
subsets might define the antitumor and/or inflammatory immune
response within the tumor microenvironment that results in either
tumor eradication or tolerance induction and disease progression.
In our recent studies investigating the therapeutic role of adop-
tively transferred Th1-like effector cells in patients with ovarian
cancer, we reported that autologous IFN-γ-secreting CD4 effector
cells used in the treatment of long-term surviving patients co-
produced higher levels of CD4 effector cell-derived IL-10 when
compared to that of short-term survivors. We suggest that such
heightened or variable levels of effector cell-derived IL-10, either
in combination with IFN-γ or alone, may contribute, in part,
to enhancing patient antitumor responses by modulating select
effector T cell subsets, such as CD4+ TReg cells and their subpop-
ulations. Conceivably, such modulation in effector cell population
dynamics could affect the balance between effective and ineffective
antitumor responses and patient survival. Although the molecu-
lar mechanisms and roles underlying the effects of IL-10 have not
been well characterized, the biological activities of IL-10 in tumor
immunity and pathology appear highly context-dependent.
THE TH17 AND IL-17 PARADOX
IL-17 secreting Th cells (Th17) have been implicated in promoting
inflammation responsible for immunopathology in both cancer
and several autoimmune disorders. Studies in various murine
tumor models have suggested that Th17 cells may be associated
with tumor initiation and growth in the context of chronic inflam-
mation (Kawakami et al., 2009; Wang et al., 2009; Wu et al., 2009b).
In patients with hormone-resistant prostate cancer, an inverse cor-
relation has been reported between pretreatment circulating levels
of Th17 cell numbers and time to disease progression suggest-
ing that Th17 cells may accelerate tumor development in such
patients (Derhovanessian et al., 2009). Alternatively, others have
suggested that Th17 cells may contribute to protective antitumor
responses in select human malignancies whereas Th17-associated
cytokines may be the contributing factors related to tumor initia-
tion and growth. In studies utilizing various genetically modified
murine tumor models, investigators have shown that endogenous
IL-17 (such as IL-17 derived from Th17 cells infiltrating sites of
tumor growth) could promote tumor growth by inducing tumor
vascularization, suggesting that the cellular targets of IL-17 in the
tumor microenvironment can be vascular endothelial cells, stro-
mal cells, and cells of the tumor itself (Numasaki et al., 2003;
Wilke et al., 2011). Later studies showed that IL-17 induced a wide
range of angiogenic mediators (Numasaki et al., 2004; Takahashi
et al., 2005; Honorati et al., 2006), including vascular endothelial
growth factor (VGEF), that markedly promotes inflammation and
tumor angiogenesis. Alternatively, IL-17 has been shown to induce
IL-6 production from tumor cells and tumor-associated stromal
cells, which in turn activate STAT-3, an oncogenic transcription
factor that upregulates pro-survival and pro-angiogenic gene lev-
els in transformed cells (Wang et al., 2009). Furthermore, IL-17
has been shown to selectively enhance the production of angio-
genic chemokines such as CXCL1, CXCL5, CXCL6, and CXCL8 in
tumor cells and epithelial cells (Numasaki et al., 2005; Lee et al.,
2008). Thus, the biological activities and tumor-promoting effects
of endogenous IL-17-mediated inflammatory responses appear
to be dependent on differences in local cytokine concentrations,
bioavailability, and presence of select responding target tissues.
Moreover, IL-17 appears highly context-dependent with respect
to tumor type, stages of development, and host immune status as
cytokine-mediated effects have been shown to be heightened in
immunocompromised animals (Murugaiyan and Saha, 2009).
Alternatively, pre-clinical murine tumor studies have cor-
related the presence of intratumoral Th17 cells with reduced
tumor growth and effective antitumor immunity (Muranski et al.,
2008; Martin-Orozco et al., 2009). Polarized Th17 cells have
been observed in distinct human cancer types, including colon,
melanoma, pancreatic, hepatocellular, and ovarian (Kryczek et al.,
2009a). In clinical studies, patients with advanced ovarian cancer
were observed to possess elevated levels of both intratumoral Th17
cell numbers and IL-17 concentrations within patient ascites that
correlated with improved survival (Kryczek et al., 2009a; Wilke
et al., 2011). Similar results have been observed in patients with
other malignancies suggesting a beneficial role for Th17 cells in
cancer (Sfanos et al., 2008; Ye et al., 2010; Chen et al., 2011). More-
over, Th17 cells have been observed to be negatively correlated
with TReg cells and positively correlated with effector immune
cells including IFN-γ-secreting Th1 cells, cytotoxic CD8 T cells,
and NK cells within the tumor microenvironment (Kryczek et al.,
2009a; Zou and Restifo, 2010; Wilke et al., 2011). However, their
roles and mechanisms of action in the antitumor response are
not well understood. It has been suggested that possible protec-
tive mechanism(s) mediated by Th17 cells include their capacity
to secrete multiple and functionally distinct cytokines such as IL-
17A, IL-17F, IL-22, and IL-21. For example, IL-21 production has
been shown to sustain CD8 T cell responses (Moroz et al., 2004;
Zeng et al., 2005; Frederiksen et al., 2008). Moreover, Th17 cells
have been shown to produce the chemokine CCL20 which can
promote DC trafficking to the sites of tumor growth in a CCL20-
CCR6 dependent manner. Recruitment of such DCs can effectively
result in the priming and activation of CD8 T cells that result in
enhanced CTL activity. In addition, IL-17 has been shown to pro-
mote maturation of DC progenitors (Antonysamy et al., 1999)
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and induce IL-12 production from macrophages (Jovanovic et al.,
1998). Thus, these studies suggest that the combined cellular prod-
ucts from both Th17 and additional immune cells infiltrating the
tumor, and the interaction between these cell types, may play a
role in the balance between effective antitumor immunity and
pro-tumor responses.
Investigations on the association between Th17 cells and
promising clinical outcomes in cancer patients, have suggested
a link and close interplay between the Th17 and Th1 cell lineages
(Kryczek et al., 2009a; Marshall et al., 2012). Within this posi-
tive association between intratumoral Th17 and IFN-γ-secreting
Th1 cells, human Th17 cell populations producing both IL-17
and IFN-γ have been identified (Annunziato et al., 2007; Hamaï
et al., 2012). It has been reported that these dual cytokine secret-
ing cell populations are exclusively derived from Th17 cells and
not initially differentiated Th1 cells (Hirota et al., 2011). These
“converted” and/or “re-differentiated” Th17 cells express the Th1
related transcription factor T-bet in addition to the IL-17-related
transcription factor ROR-γt (Annunziato et al., 2007). Stimulation
by IL-12 rapidly down-regulated IL-17 production and induced
expression of IFN-γ through enhanced T-bet expression and the
subsequent down-regulation of ROR-γt expression (Annunziato
et al., 2007; Annunziato and Romagnani, 2010; Lazarevic et al.,
2011). Moreover, this shift in phenotype appeared to be facilitated
by the low but constitutive expression of IL-12Rβ2 among Th17
cells (Annunziato et al., 2007; Lee et al., 2009). Thus these findings
provided a molecular basis to explain Th17 cell plasticity and/or
conversion to the Th1 cell lineage and further supports the concept
that such events can occur within portions of the Th17 cell popula-
tion under inflammatory conditions such as that of a hostile tumor
environment in vivo (Muranski et al., 2008; Bending et al., 2009;
Martin-Orozco et al., 2009b; Annunziato and Romagnani, 2010;
Murphy and Stockinger, 2010; Nistala et al., 2010; Hamaï et al.,
2012; Marshall et al., 2012). This process of Th17 cellular plas-
ticity appears highly context-dependent and can be influenced,
in part, by the cytokine milieu produced by innate immune cells
within the inflammatory environment. Consequently, such con-
version of the Th17 cell population into the Th1 cell lineage,
can have important biological implications in tumor immunity
and disease progression. As mentioned earlier, both effector cell-
derived IL-17 and IFN-γ can potentially promote or suppress the
generation of effective immune responses through a myriad of
different mechanisms (Xiao et al., 2009; Tosolini et al., 2011).
Although the role of Th17 cells co-producing IL-17 and IFN-γ
is not clear, it has been suggested that both cytokines can either
synergistically or independently induce the production of func-
tionally diverse chemokines within the tumor environment which
in turn can recruit and promote distinct types of effector T cells
and/or other immune cells that can influence antitumor immune
responses and mediate tumor regression or progression (Kryczek
et al., 2009b; Martin-Orozco et al., 2009; Kesselring et al., 2010).
Thus, it is conceivable that the relative quantity and/or duration of
either IL-17 or IFN-γ produced by such double-positive cytokine
secreting Th17 cell subpopulations may define the antitumor
immune response. Moreover, the type of tumor, the cells within
its microenvironment, and their responsiveness to the various
tumor-associated cytokines may further promote and influence
an imbalance between pro-tumor verses antitumor effects. For
example, recent studies in the murine system by Huber et al., have
shown that both IL-17- and IL-17/IFN-γ-producing Th17 cells
express higher surface levels of the IL-10Rαwhen compared to that
Th1 cells and that the potential antitumor or pro-tumor effects of
the Th17-mediated inflammatory response can be more readily
suppressed by endogenously produced IL-10 (Huber et al., 2011).
Since many lineage-related tumor types can initially possess and
generally favor similar microenvironments that can induce and
selectively affect specific effector T cell-mediated responses, this
may partially explain why Th17 cells have been observed and asso-
ciated with protective tumor immunity in only some cancers but
not all (Kryczek et al., 2009a). The pro-tumor verses antitumor
effects of such Th17 effector cell subpopulations may thus rep-
resent a “balance” between IL-17 and IFN-γ cytokine production
that can facilitate either tumor promotion or regression. Further
identification and characterization of the mechanisms involved in
the induction of tumor-reactive Th17 effector cells and their activ-
ities in cancer patients may offer significant advantages for future
treatment strategies of human malignancies.
CD4+ TREG CELL SUBPOPULATIONS IN IMMUNE REGULATION AND
THE ANTITUMOR RESPONSE
The immunoregulatory roles of CD4+ TReg cell subsets have
been associated with the prevention of immunopathology dur-
ing excessive and/or unwanted inflammation and prevention of
autoimmune disease. However, in the context of cancer, such cells
have been associated with facilitating the suppression of the anti-
tumor response through various tolerance induction and tissue
homeostatic mechanisms. However, the role and prognostic value
of TReg cells in cancer has recently been disputed (Wilke et al.,
2010; Tosolini et al., 2011; deLeeuw et al., 2012). It has initially been
reported that high TReg cell frequencies infiltrating the tumor
environment correlate with more advanced disease and poor prog-
nosis in patients. In ovarian, pancreatic, and breast cancer patients,
either systemic or local FoxP3+ TReg cell expression has been asso-
ciated with both a poor prognosis and diminished survival rates
(Woo et al., 2001; Liyanage et al., 2002; Wolf et al., 2003, 2005;
Curiel et al., 2004; Li et al., 2005; Bates et al., 2006; Merlo et al.,
2009). Curiel and colleagues reported that the presence of high
numbers of CD4+FoxP3+ T cells in malignant ascites of patients
with ovarian carcinomas correlated with advanced tumor staging
and reduced survival. Alternatively, in colorectal cancer, several
investigators did not find any differences between patients with
high or low TReg cell infiltration (Loddenkemper et al., 2006)
whereas others have found an improved survival associated with
a high density of local and systemic FoxP3+ cells suggesting no
major immunosuppressive role of TReg cells in colorectal cancer
(Salama et al., 2009). Moreover, it has been suggested that the pres-
ence and levels of various TReg cell subsets in cancer patients may
be beneficial to survival (Alvaro et al., 2005; Erdman et al., 2005;
Grivennikov et al., 2010; Wilke et al., 2010; deLeeuw et al., 2012).
None-the-less, in early clinical studies investigating adoptive T
cell transfer therapies in patients with select cancer types, it was
observed that TReg cell depletion prior to therapy can enhance
clinically relevant immune responses to such treatments (Muran-
ski et al., 2006; Wrzesinski et al., 2007; Dudley et al., 2008; Porter
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et al., 2011; Rosenberg et al., 2011; Le and Jaffee, 2012; Yao et al.,
2012). These findings fit with the general notion that TReg cells
suppress adaptive immune responses and led many groups to pur-
sue various cytoablative strategies to deplete such cells from cancer
patients receiving immunotherapy as a means to enhance clini-
cal responses. In contrast, others have observed the induction of
effective antitumor responses following administration of various
immunotherapeutic strategies in the absence of cytoablative treat-
ments, and have suggested that such responses are likely due to the
balance between effector T cells (i.e., either CD4 or CD8) and TReg
cells within treated cancer patients (Alvaro et al., 2005; Quezada
et al., 2006; Hunder et al., 2008; Le and Jaffee, 2012; Liu et al.,
2012a). Along these lines, in our clinical study investigating adop-
tive T cell therapy using autologous Th1-like effector cells in the
treatment of ovarian cancer patients, we observed enhanced T cell-
mediated immune responses in long-term surviving patients that
appeared to correlate with differences in their ratios of “inducible”
verses “natural” TReg cell subpopulations when compared to that
of short-term survivors receiving similar treatments (Dobrzan-
ski et al., 2009, 2011). We suggest that such patient responses
did not appear to be dependent on TReg cell numbers but upon
their subpopulation ratios within responding patients. Although
the precise mechanisms by which these regulatory cells and their
various subpopulations (and those that have yet to be defined)
potentially function to establish or rebalance immune cell home-
ostasis and sustain the “balance” between tumor immunity, sup-
pression, and tolerance remains poorly understood, it could be
speculated that a collaboration and cross-talk among these var-
ious TReg subpopulations are required for the maintenance and
control of effective immune responses. Thus, a conceivable role for
co-therapeutic approaches targeting modulation, and not deple-
tion, of the TReg cellular network in patients with select tumor
types may be an alternative and potentially effective therapeutic
approach to treating cancer patients.
Select chemokines and their corresponding receptors have been
shown to play a role in the recruitment of specific T cell subsets
into tumors and sites of inflammation (Sallusto et al., 1997, 1998;
Bonecchi et al., 1998; Loetscher et al., 1998; Hirai et al., 2001;
Iellem et al., 2001; Muthuswamy et al., 2012). Among human
TReg cells, the chemokine receptor CCR4, and its ligands CCL22
and CCL17, are believed to be the most predominant chemokine-
related mechanism responsible for TReg cell trafficking to tumors
(Iellem et al., 2001). It has been reported that production of
the chemokine CCL22 is associated with human ovarian cancer
(Iellem et al., 2001; Curiel et al., 2004) and has also been observed
in other types of malignancies, such as gastric cancer (Haas et al.,
2008, 2009), Hodgkin’s lymphoma (Ishida et al., 2006), and breast
cancer (Menetrier-Caux et al., 2009). Blockade of CCL22 in vivo
significantly reduced human TReg cell trafficking to ovarian car-
cinomas (Curiel et al., 2004). In a study on gastric cancer, CCL22
and CCL17 appeared to be both important in recruiting TReg
cells to such tumors as demonstrated by in vitro migration assays
(Mizukami et al., 2008). Additional observations in this same study
further indicated that the levels of intratumoral CCL22 and CCL17
appeared to correlate with increased levels of TReg cell localiza-
tion within these tumors at early stages of development. Besides
the CCR4 chemokine receptor/ligand interaction, CCR5/CCL5
may also selectively recruit TReg cells to pancreatic tumors as
shown in both human and murine systems (Tan et al., 2009). In
addition, the chemokine CCL20 shows high affinity to TReg cells
expressing CCR6 and has been shown to mediate selective CCR6+
TReg cell trafficking (Kleinewietfeld et al., 2005). In any instance,
both naturally occurring (nTReg) or inducible (iTReg) CD4+
TReg cell subpopulations may become enriched within tumors,
through a variety of different chemokine receptor/ligand interac-
tions. Furthermore, cytokines and chemokines produced, in part,
by either tumor cells, tumor infiltrating lymphocytes, and/or APCs
within the tumor milieu may preferentially support such TReg cell
expansion, retention, survival, and in some cases, their “further”
differentiation and/or change in phenotype (Campbell and Koch,
2011). Following recruitment to sites of inflammation, one of the
major functions of CD4+ TReg cell subsets is to maintain and/or
restore local immune cell homeostasis during polarized Th1, Th2,
and Th17 cell-mediated immune responses. This led to the iden-
tification and observation that human Th cell subsets and TReg
cells appear to undergo functional specialization in parallel result-
ing in the development of functionally distinct TReg cell subsets
capable of co-localizing with and effectively regulating different
types of Th cell responses in vivo (Hall et al., 2011; Duhen et al.,
2012). Although the precise mechanisms by which these various
TReg cell subpopulations maintain or restore immune homeosta-
sis at sites of inflammation and/or tumor growth is unknown, it
is conceivable that such interactions that involve the local modu-
lation of the naïve, effector, and memory Th cell pools can further
influence antitumor responses that may favor either disease pro-
gression or regression. In addition, evidence is accumulating in
several pre-clinical murine experimental models that a portion of
CD4+ TReg cells can down-regulate FoxP3 expression and their
associated regulatory properties and in some cases acquire an effec-
tor cell phenotype that expresses IFN-γ and/or IL-17 (Gavin et al.,
2007; Strauss et al., 2007; Miyara et al., 2009; Oldenhove et al., 2009;
Martin et al., 2010; Whiteside, 2010; Miyao et al., 2012). Although
this concept and process of cellular conversion and/or plasticity
among CD4+FoxP3+ TReg cells remains controversial (Rubtsov
et al., 2010), it is clear that the biological properties of CD4 TReg
cells and their subpopulations are heterogeneous and influenced
by the tumor environment in which they infiltrate (Hamann, 2012;
Sainz-Perez et al., 2012).
Alternatively, CD4+ TReg cells may possess other underappre-
ciated anti-cancer functions. For example, such cells may have the
ability to limit the extent and potential of inflammatory responses
to induce tumor development and carcinogenesis. Using a murine
herpes viral model, investigators observed that TReg cell-mediated
down-modulation of inflammatory responses in secondary lym-
phoid tissues can actually optimize ensuing immune responses
to local infection by more effectively redirecting it to sites of
initial infection (Lund et al., 2008). These investigators further
suggested that this down-modulation in inflammation within
distal secondary lymphoid tissues following local viral infection
can facilitate efficient effector T cell migration to sites of pri-
mary infection and more effectively promote disease eradication.
Conceivably, this can be a concept that can also be applied to local
sites of carcinogenesis and primary tumor growth. Moreover, oth-
ers have suggested that, in colorectal and gastric cancers, CD4+
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TReg cells may inhibit tumor-promoting inflammatory responses
induced by local microbes, which may help explain their presence
and favorable association with outcomes to these cancers (Haas
et al., 2009; Zamarron and Chen, 2011). Thus the initial views
on the role of TReg cells in carcinogenesis, tumor pathology, and
tumor immunity appear oversimplified and in fact appear highly
context-dependent with respect to their interactions with different
components of a dynamic tumor environment.
SUMMARY AND OVERALL THOUGHTS
The immune system has the capacity to either obstruct tumor
development and deter established tumors, or to promote car-
cinogenesis and tumor progression. Here, we reviewed how CD4
T cells and their various functionally distinct subpopulations
contribute to the antitumor immune response and potentially
influence this process. Several key principles emerge. Distinct
effector and memory CD4 T cell subsets have important roles
in the antitumor response. Key among these roles is the pro-
vision of orchestrating and/or regulating other immune cells
that result in promoting tumor eradication, long-term tumor
immunity, and establishing or rebalancing immune cell home-
ostasis within the tumor environment. Such roles are mediated, in
part, by the production of signature cytokines by specific CD4
T cell lineages and through direct cytotoxic effects on tumor
cells. The efficacy of such CD4 effector T cell responses may not
only depend on memory cell generation, phenotype, and their
functional capacity to interact with other immune cell popula-
tions, but also in some cases, on their ability to evolve through
“cellular plasticity” within the hostile tumor environment. Con-
ceivably, this trait of “cellular Darwinism” by the various CD4 T
cell lineages could endow them with considerable flexibility to
procure effective tumor immunity. Alternatively, it appears that
such CD4 T cell subsets and their signature cytokines can also
contribute and facilitate tumor-promoting activities. This may be
due, in part, on the abilities of select CD4 T cell lineages and
their subpopulations to modulate effector cell population dynam-
ics and thus affect the balance between effective and ineffective
antitumor responses. Achieving an “appropriate cellular balance”
appears highly context-dependent. Further studies on the biolog-
ical activities and mechanisms of how the various polarized CD4
effector and/or memory T cell subsets influence and/or facilitate
the immune response as a whole in patients with different types of
cancers should further enhance the development of more effective
cancer treatment strategies.
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